Microarray analysis of miRNA expression in 30 GBMs.

<p><b>A.</b> Unsupervised hierarchical clustering of GBMs (horizontal dimension) and 102 miRNAs (vertical dimension) derived from a variance analysis. Over-expressed genes are represented in red and under-expressed ones in blue. <b>B.</b> The projection to latent structures discriminant analysis (PLS-DA) score scatter plot of the first 2 components. This PLSDA analysis discriminates the differences between GBM with high-level of <i>EGFR</i> amplification (n = 13) versus GBM non-amplified <i>EGFR</i> (n = 10). The symbols correspond as follows: red triangle, GMB with high level of amplified <i>EGFR</i> samples; blue square, non-amplified <i>EGFR</i> samples; green circle, samples with a low level of <i>EFGR</i> amplification.</p

Real-Time RT-PCR analysis of EGFR, mir-200c, CDH1 and ZEB1 expression.

<p>Results are representative of 30 different samples. Changes in mRNA expression are reported as mean and standard error with respect to non-amplified <i>EGFR</i> group using the 2^−ΔΔCt method. Statistically significant expression changes (p<0.05) are marked with an *. <b>A.</b> EGFR mRNA expression in the GBM groups with different levels of <i>EGFR</i> amplification. The results were normalized to the actin housekeeping gene. <b>B.</b> miR-200c expression in tumor biopsies from the three studied groups. The results were normalized to the U66 housekeeping gene for miR-200c. <b>C.</b> CDH1 mRNA expression and <b>D</b>. ZEB1 mRNA expression in biopsies from the three studied groups. The results were normalized to the actin housekeeping gene.</p

Argentina-Alzheimer's disease neuroimaging initiative (Arg-ADNI): neuropsychological evolution profile after one-year follow up

<div><p>ABSTRACT The Argentina-Alzheimer's disease neuroimaging initiative (Arg-ADNI) study is a longitudinal prospective cohort of 50 participants at a single institution in Buenos Aires, Argentina. Longitudinal assessments on a neuropsychological test battery were performed on 15 controls, 24 mild cognitive impairment (MCI) patients and 12 Alzheimer's disease (AD) dementia patients. In our study population, there was a high prevalence of positive AD biomarkers in the AD group, 92.3% (12/13); and a low prevalence in the normal controls, 20%; almost half (48%) of the patients diagnosed with MCI had positive amyloid detection. After a one year, the significant differences found at baseline on neuropsychological testing were similar at the follow-up assessment even though the AD group had significantly altered its functional performance (FAQ and CDR). The exception was semantic fluency, which showed greater impairment between the AD group and MCI and normal controls respectively. For these tests, the addition of AD biomarkers as a variable did not significantly alter the variations previously found for the established clinical group's model. Finally, the one-year conversion rate to dementia was 20% in the MCI cohort.</p></div